XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.5.0.2

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 21, 2016 | May 30, 2016 | Mar. 01, 2016 | Sep. 16, 2014 | Aug. 31, 2016 | Apr. 30, 2016 | Mar. 31, 2016 | Nov. 30, 2015 | Aug. 31, 2015 | Mar. 31, 2015 | Jun. 30, 2014 | Jun. 30, 2013 | Feb. 29, 2012 | Sep. 30, 2016 | Dec. 31, 2013 | Dec. 31, 2010 | Dec. 31, 2009 | Sep. 30, 2016 | Dec. 31, 2013 | Dec. 31, 2007 | Jul. 31, 2016 | Dec. 31, 2015 | Jul. 31, 2015
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 147,000,000 |  |  |  |  |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  | $ 12,500,000 |  |  |  | $ 0 |
ONZEALDTM (NKTR-102) [Member] | Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca-ProStrakan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestones, royalties and sales milestones |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of out-of-pocket costs reimbursed by partner | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement exclusivity expiration date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Sep. 30, 2018 |  |  |  |  |
License agreement exclusivity negotiation period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 months |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of regulatory and commercial milestones |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be received upon first commercial sales |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment to be received upon first commercial sale after final regulatory approval |  | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be received upon first achievement of annual net sales target |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  | $ 12,500,000 |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | European Territory Except Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable portion of upfront payment |  | $ 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  |  |  | 4,000,000 |  |  |  |  |
AstraZeneca AB [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability to AZ for DTC advertising payments |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  | $ 5,000,000
Reduction of revenue |  |  |  |  |  |  |  |  |  | (10,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIKTM and MOVANTIKTM fixed-dose combination program [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000,000 |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential contingent payments based on development events |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |  |  |  | 75,000,000 |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of post approval study costs to repay |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential reduction in royalties |  |  |  | $ 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential reduction in U.S. royalty rate for repayment |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | AstraZeneca-ProStrakan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 0 |  |  |  |  |
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement |  |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner |  |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payment recognized as revenue |  |  |  |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 0 |  |  |  |  |
Development milestones achieved |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Roche [Member] | MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received for product delivered in 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,600,000 |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,000,000 |  |  |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,900,000 |  |  |  | 1,900,000 |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,400,000 |  |  |  | 20,400,000 |  |  |  |  |
Bayer Healthcare LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,200,000 |  |  |  | 18,200,000 |  |  |  |  |
Payment made to Bayer for cost of Phase 3 clinical trial |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |  |  |
Bayer Healthcare LLC [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  | $ 19,800,000 |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,200,000 |  |  |  | 17,200,000 |  |  |  |  |
Potential future development milestones upon acceptance for review of regulatory approval |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |  | 2,500,000 |  |  |  |  |
Other [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 9,400,000 |  |  |  | $ 9,400,000 |  |  |  |  |

X
- Definition Consideration received for product delivered. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForProductDelivered
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payment recognized as revenue. + References No definition available. + Details
Name: | nktr_ContingentPaymentRecognizedAsRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | nktr_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase decrease in revenue. + References No definition available. + Details
Name: | nktr_IncreaseDecreaseInRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability to AZ for DTC advertising payments. + References No definition available. + Details
Name: | nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability for refundable upfront payment. + References No definition available. + Details
Name: | nktr_LiabilityForRefundableUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement exclusivity expiration date. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityExpirationDate
Namespace Prefix: | nktr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement exclusivity negotiation period. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityNegotiationPeriod
Namespace Prefix: | nktr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment to be received upon first commercial sale after final regulatory approval. + References No definition available. + Details
Name: | nktr_MilestonePaymentToBeReceivedUponFirstCommercialSaleAfterFinalRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be received upon first achievement of annual net sales target. + References No definition available. + Details
Name: | nktr_MilestonePaymentsToBeReceivedUponFirstAchievementOfAnnualNetSalesTarget
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be received upon first commercial sales. + References No definition available. + Details
Name: | nktr_MilestonePaymentsToBeReceivedUponFirstCommercialSales
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable portion of upfront payment. + References No definition available. + Details
Name: | nktr_NonRefundablePortionOfUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment made to Bayer for cost of Phase 3 clinical trial. + References No definition available. + Details
Name: | nktr_PaymentForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of out of pocket costs reimbursed by partner. + References No definition available. + Details
Name: | nktr_PercentageOfOutOfPocketCostsReimbursedByPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of post approval study costs to repay. + References No definition available. + Details
Name: | nktr_PercentageOfPostApprovalStudyCostsToRepay
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net sales. + References No definition available. + Details
Name: | nktr_PercentageOfRoyaltyOnNetSales
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontMilestonesRoyaltyAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment, market access milestones, royalties and sales milestones. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonesRoyaltiesAndSalesMilestones
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent payments based on development events. + References No definition available. + Details
Name: | nktr_PotentialContingentPaymentsBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential development milestones upon acceptance for review of regulatory approval. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestonesUponAcceptanceForReviewOfRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential reduction in future royalty payments to repay post approval studies. + References No definition available. + Details
Name: | nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential royalty reduction on sales to repay post-approval study if required. + References No definition available. + Details
Name: | nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized from upfront payment. + References No definition available. + Details
Name: | nktr_RevenueRecognizedFromUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received by Our collaboration partner under sublicense arrangement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedByOurCollaborationPartnerUnderSublicenseArrangement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ONZEALDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_TR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithProStrakanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_DaiichiSankyoEuropeGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=nktr_EuropeanTerritoryExceptTurkeyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_PEGASYSAndMIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_FovistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |